Emerging PARP inhibitors for treating breast cancer - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Expert Opinion on Emerging Drugs Année : 2018

Emerging PARP inhibitors for treating breast cancer

Résumé

Some breast cancers harbor defects in DNA repair pathways, including BRCA1 and BRCA2 mutations, leading to a genomic instability. Compromised DNA-damage repair response is found in 11 to 42% of triple negative breast cancers, with a frequency varying according to family history and ethnicity. The oral PARP inhibitors are a promising strategy in breast cancer exploiting Homologous Deficient Recombination deficiency (HRD) by a synthetic lethal approach. Several PARP inhibitors have currently reached early phase trials with studies on going in the adjuvant, neoadjuvant and metastatic setting. Area covered: Here, we review completed and ongoing trials with PARP inhibitors as well as their mechanisms of activity and acquired resistance. Expert opinion: PARP inhibitors show promising results in breast cancer. However, several issues are raised including the identification of biomarkers to predict treatment response and strategies to counteract emerging resistance.

Domaines

Cancer
Fichier non déposé

Dates et versions

inserm-01977751 , version 1 (11-01-2019)

Identifiants

Citer

Marie Robert, Anne Patsouris, Jean-Sébastien Frenel, Carole Gourmelon, Paule Augereau, et al.. Emerging PARP inhibitors for treating breast cancer. Expert Opinion on Emerging Drugs, 2018, 23 (3), pp.211-221. ⟨10.1080/14728214.2018.1527900⟩. ⟨inserm-01977751⟩
47 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More